Pearl Bio, a synthetic biology company backed by Khosla Ventures, announced that it has entered into a license, collaboration and option agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to discover biologic therapies comprising non-standard amino acids.